Document 0082
 DOCN  M9440082
 TI    Demonstration of reversed IL-7R/IL-2R expression on CD3+ TIL toward
       IL-2R with increasing proximity to malignant prostatic cells (Meeting
       abstract).
 DT    9404
 AU    Kramer G; Steiner G; Reinwald C; Schollhammer A; Binder S; Mehrawi M;
       Boltz G; Marberger M; Dept. of Urology, Univ. of Vienna, Austria
 SO    FASEB J; 7(3):A428 1993. Unique Identifier : AIDSLINE ICDB/94697227
 AB    To obtain exact information on the location and activation marker
       expression of individual lymphocyte subsets in situ and to arrive at
       inferences about their function, serial sections of 25 untreated cancer
       tissues were analyzed for intraepithelial (ie), periepithelial (pe) and
       perivascular (pv) CD3+ TIL/mm2. In general, CD3+ TIL ranged from 12/mm2
       to 217/mm2 independently of tumor grade. 22.7% of CD3+ TIL were located
       pe within 0.05 mm of the epithelium, whereas the majority (65%) were
       more distant, only 8.3% being located ie and 3.9% pv. The CD4:CD8 ratio,
       which was 2.3:1 overall, showed a tremendous shift toward CD8+ cells of
       1.08:1 in pe and 0.34:1 in ie areas. Overall TIL showed significant
       reactivity with anti-IL-7R (29.4/mm2) and anti-IL-2R (15.9/mm2)
       antibodies. The pattern of pe IL-7R+ (3.68/mm2) and IL-2R+ (2.86/mm2)
       cells reconfirms the drastic decrease seen in ie areas with IL-7R+
       (0.03/mm2) and IL-2R+ (0.13/mm2) cells. Most interestingly, the ratio of
       IL-7R-:IL-2R-bearing cells showed a drastic shift toward IL-2R
       expression from 4.2:1 in pv to 0.22:1 in ie areas. These findings
       reflect the inability of T cells to invade glandular structures, and the
       loss of IL-7R expression within these immunosuppressed areas indicates
       the potential usefulness of IL-7R-bearing cells in immunotherapy of
       prostate cancer.
 DE    Antigens, CD3/IMMUNOLOGY  CD4-CD8 Ratio  Human  Immunotherapy
       Lymphocytes, Tumor-Infiltrating/METABOLISM  Male  Prostatic
       Neoplasms/IMMUNOLOGY/*METABOLISM/THERAPY  Receptors,
       Interleukin/IMMUNOLOGY/*METABOLISM  Receptors,
       Interleukin-2/IMMUNOLOGY/METABOLISM  Tumor Cells, Cultured  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).